ArticleJournal of thoracic disease2025

Camrelizumab combined with neoadjuvant docetaxel, oxaliplatin, and S1 as induction therapy for locally advanced esophageal squamous cell cancer: a real-world single-center cohort study.

Guanghui Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.